Updated on November 29, 2025, with new Latin American Spanish and Mandarin audio versions to help readers worldwide access this content.
🎧 ▶️ Press the play button below to listen in English.
🇪🇸 Spanish (Latinoamérica)
Este audio explica por qué los betabloqueadores siguen siendo importantes después de un infarto y por qué suspenderlos de golpe puede ser peligroso.
Presiona el botón de reproducir para escuchar.
🇨🇳 中文（简体）
本音频说明为什么心脏病发作后仍然需要使用β受体阻滞剂，以及突然停药可能带来的危险。
请按下方的播放按钮收听。
Introduction
In August 2025, two major studies on beta-blockers after a heart attack were published in The New England Journal of Medicine. The results made headlines around the world. Some news outlets even ran bold statements like: “Common heart drug taken by millions found useless, possibly risky.”
It’s no surprise that many patients are now worried. Beta-blockers are among the most widely prescribed heart medicines. If you take one, you may be wondering: Should I keep taking it? Is it still protecting me?
The truth is more complex than the headlines suggest. The two studies reached different conclusions, and a new meta-analysis that combines them with two other trials provides a clearer picture.
The takeaway is this: beta-blockers still have an important role after a heart attack for many patients — and stopping them suddenly can be dangerous.
What Beta-Blockers Do
Beta-blockers are medicines that “slow things down” for your heart. They work by blocking the effects of adrenaline, the stress hormone that makes your heart beat faster and harder.
By doing this, beta-blockers:
- Lower your heart rate so the heart doesn’t have to work as hard.
- Reduce blood pressure, taking strain off the blood vessels.
- Protect the heart muscle by lowering its oxygen demand.
For decades, doctors have prescribed beta-blockers after a heart attack because they can:
- Prevent dangerous heart rhythms (like atrial fibrillation or ventricular tachycardia).
- Reduce chest pain (angina).
- Lower the risk of another heart attack or sudden death.
Even today, they remain essential for patients with weakened heart pumping function (Heart Failure) or those with specific rhythm problems.
The REBOOT Trial (Spain & Italy)
One of the new studies is called REBOOT. It enrolled more than 8,400 patients in Spain and Italy who had just suffered a heart attack. All had a heart pumping function above 40% — meaning their hearts were not severely weakened.
Patients were randomly assigned to either take a beta-blocker or avoid beta-blockers. Doctors then followed them for almost 4 years to see if beta-blockers made a difference in preventing:
- Death from any cause
- Another heart attack
- Hospitalization for heart failure
Which beta-blockers were used?
Unlike the other study, REBOOT allowed doctors to choose from several different beta-blockers. These included metoprolol, bisoprolol, carvedilol, nebivolol, and atenolol. The doses were not uniform, and treatment strategies varied between hospitals.
The results
There was no difference between the two groups. A similar number of patients experienced repeat heart problems, regardless of whether they were taking beta-blockers or not.
Researcher’s conclusion:
“Beta-blocker therapy showed no evidence of benefit across the study population of patients with MI managed invasively who had LVEF >40%.” – Dr. Borja Ibáñez (NEJM, 2025)
What this means
In patients whose hearts are still pumping normally after a heart attack, and who receive today’s standard treatments (like stents, statins, and blood thinners), beta-blockers may not always add extra protection.
But keep in mind: because REBOOT used different types and doses of beta-blockers, the results may reflect this variety, rather than the drugs being ineffective altogether.
The BETAMI DANBLOCK Trial (Norway & Denmark)
The other major study was called BETAMI–DANBLOCK. It included about 5,500 patients in Norway and Denmark who had recently suffered a heart attack. Like REBOOT, these patients all had a heart-pumping function of at least 40%, and most had a normal function above 50%. Almost all of them received modern treatment such as stents, statins, and blood thinners.
Which beta-blocker was used?
Here, the approach was much more consistent than in REBOOT. Nearly 95% of patients were given long-acting metoprolol, usually starting at a low dose of 50 mg. Very few patients used other beta-blockers, such as bisoprolol, carvedilol, or nebivolol.
The results
Over 3.5 years of follow-up, patients on metoprolol had fewer major cardiovascular events than those who took no beta-blocker:
- 14.2% vs. 16.3% overall
- Biggest difference: repeat heart attacks were lower (5.0% vs. 6.7%).
- Death rates were almost the same in both groups (4.2% vs. 4.4%).
Researcher’s conclusion:
“Our findings suggest that, despite advances in contemporary MI treatment, the beneficial effects of beta-blocker therapy remain clinically relevant.” – Prof. Eva Prescott (NEJM, 2025)
What this means
In contrast to REBOOT, BETAMI–DANBLOCK suggests that consistent treatment with metoprolol may still protect patients from having another heart attack, even when their heart function looks normal.
The Meta-Analysis: Putting All Four Trials Together
When researchers combined data from REBOOT, BETAMI–DANBLOCK, DANBLOCK, and CAPITAL-RCT (Japan) and focused on people with mildly reduced heart function (EF 40–49%), a clear pattern showed up: beta-blockers helped.
- Who was analyzed: 1,885 patients with EF 40–49%, no heart failure.
- Main result: The combined risk of death, another heart attack, or heart failure was lower with beta-blockers (10.7%) than without (14.4%) → 25% relative reduction (HR 0.75, 95% CI 0.58–0.97).
- Each part of the outcome moved in the same direction (fewer deaths, fewer new MIs, fewer HF events with beta-blockers), though not every single component reached statistical significance by itself.
What this means for readers:
If your heart was even a bit weakened after a heart attack (EF in the 40–49% range), the best current evidence says a beta-blocker reduces your chance of serious problems.
For those with fully normal EF (≥50%), the trials disagree, so doctors will individualize decisions—don’t stop on your own.
Beyond the Headlines: Risks, Side Effects, and Real-World Lessons
As an emergency room physician, I’ve seen firsthand what can happen when patients suddenly stop taking their beta-blockers. Some came in with chest pain and had another heart attack. Others developed atrial fibrillation with rapid ventricular response — a dangerously fast and irregular rhythm that can lead to serious complications.
This is why it’s so important to stress: never stop a beta-blocker abruptly on your own. If you have questions after seeing headlines or hearing about new studies, the safest step is to talk with your doctor. Together, you can decide whether you still need the medication, adjust your dose, or, in some cases, safely taper off.
Other Reasons Beta-Blockers Are Prescribed
Not everyone takes beta-blockers strictly for heart attacks or heart failure. Doctors sometimes use them for other conditions, such as:
- Migraine prevention
- Anxiety, especially performance anxiety
- Essential tremor
👉 If you’re taking a beta-blocker only for one of these “off-label” uses, your doctor may have more flexibility in stopping or switching it. But always discuss it first.
Side Effects Patients Should Know About
Beta-blockers are helpful, but they are not entirely benign. Possible side effects include:
- Fatigue or low energy
- Cold hands and feet
- Vivid dreams or sleep changes
- Sexual dysfunction
- Worsening asthma in some people
- Development of insulin resistance, which can raise blood sugar levels
What This Means for Patients
- Don’t panic about headlines. The studies don’t mean beta-blockers are useless. They mean doctors now have more information to personalize care.
- Beta-blockers remain essential if you have:
- A weakened heart (EF <50%)
- Chest pain (angina)
- Heart rhythm problems (like atrial fibrillation or dangerous fast rhythms)
- High blood pressure that needs control
- If your heart function is fully normal (EF ≥50%) and you’ve had a heart attack, your doctor may decide whether you still need a beta-blocker long-term. Some patients will continue, others may not.
- Never stop suddenly. Stopping beta-blockers on your own can cause:
- Rapid heart rate (tachycardia)
- Chest pain or another heart attack
- Dangerous rhythm problems like atrial fibrillation with rapid ventricular response
- The safest step: If you’re unsure whether you should still be taking a beta-blocker, talk with your doctor before making any changes.
Bottom Line
The newest research shows that not all patients need to stay on beta-blockers after a heart attack if their heart-pumping function is entirely normal. But the studies also confirm that many patients still benefit — especially those with even mildly weakened heart function, ongoing chest pain, or rhythm problems.
What matters most is that treatment is tailored to each individual. Doctors now have stronger evidence to guide who should continue and who may safely reduce or stop.
For patients, the key takeaway is simple: do not stop your beta-blocker suddenly on your own. Sudden withdrawal can trigger fast heart rhythms or even another heart attack. Always make changes under the guidance of your doctor.
👉 Headlines may confuse, but the truth is clear: beta-blockers are still valuable tools for the right patients.
Don’t Get Sick!
💡 Support This Work
Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.
🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!
Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.
Related:
- 7000 Steps Can Save Your Heart, Brain, And Prolong Life
- HDL Raising Drugs Do Not Improve Cardiovascular and All-Cause Mortality
- Stronger Handgrip, Longer Life: What Science Now Shows
- Reduced Flexibility, Shorter Life? What This 29-Year Study Reveals
- Physical Activity Prolongs Life
- Stunning Low Doses Of Lithium Really Improve Survival
- Your Calf Muscles Could Predict Your Lifespan
- Blue Spaces, Longer Lives: Unlock Nature’s Hidden Advantage
- Low Testosterone, Higher Mortality: What Two Major Studies Reveal About Hormone Health and How to Boost It Naturally
- Pfizer and Moderna shots increase all cause mortality: Denmark study
- Big Heart Benefits From Small Efforts: Discover VILPA
- Exercise Or Statins? Choose The Powerful Path To Longevity
- Unlock Longevity Now: 8 Healthy Habits That Defy Death
- How A Duchenne Smile Boosts Mood, Love, And Longevity
- The Sit and Rise Test Predicts How Long You’ll Live
References:
- REBOOT/BETAMI/DANBLOCK/CAPITAL-RCT: Beta-blockers after MI with mildly reduced EF (an IPD meta-analysis)’ presented during HOT LINE 3 on 30 August 2025 at 11:20 to 11:30 in Madrid (Main Auditorium).
- Rossello, X. et al. “Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.” New England Journal of Medicine, Aug 30, 2025. DOI: 10.1056/NEJMoa2504735. https://www.nejm.org/doi/full/10.1056/NEJMoa2504735
- Munkhaugen, J. et al. “Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.” New England Journal of Medicine, Aug 30, 2025. DOI: 10.1056/NEJMoa2505985. https://pubmed.ncbi.nlm.nih.gov/40888716/
- Watanabe H, Ozasa N, Morimoto T, et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One. 2018;13:e0199347.
© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases
Discover more from Don't Get Sick!
Subscribe to get the latest posts sent to your email.